



ASX Announcement

September 29, 2021

## **CHM 1101 (CLTX CAR T) DATA ACCEPTED FOR PRESENTATION AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING**

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical-stage cell therapy company, is pleased to highlight the acceptance of two CHM 1101 (CLTX CAR T) abstract presentations at the Society for Neuro-Oncology (SNO) 26<sup>th</sup> annual scientific meeting being held from November 18-21, 2021. The inclusion of these abstracts in the premier global neuro-oncology meeting recognizes the importance of the development of CHM 1101 (CLTX CAR T) to the field of neuro-oncology drug development.

Clinical evaluation of the initial dose cohort in the phase 1 clinical trial for CHM 1101 (CLTX CAR T) will be presented on Friday, November 19 within abstract CTIM-29. This abstract presentation will provide new information on the safety, efficacy, and bioactivity of CHM 1101 in patients treated at the initial low dose level of  $44 \times 10^6$  cells with intratumoral administration in the ongoing phase 1 clinical trial.

**Commenting on what the Company is looking for from the information to be presented at SNO, Chimeric’s CEO and Managing Director Jennifer Chow said:**

*“These data are critical to advancing our clinical development program. At the low dose level that patients in this cohort received, we are focused on being able to establish safety and bioactivity in patients. Once we are able to further characterize the safety and bioactivity of CHM 1101, we will be able to move forward to focus on our exploration of efficacy at the higher dose levels in the trial with dual routes of administration.”*

Abstract EXTH-10, to be presented on Friday November 19, will provide further insight into the mechanism by which CHM 1101 (CLTX CAR T) recognizes glioblastoma tumor cells. These novel findings continue to advance Chimeric’s understanding of the precise composition and localization of the cell surface complex recognized by CLTX CAR T.

Acceptance of these abstracts for presentation at the 26<sup>th</sup> annual SNO meeting requires an embargo on all CHM 1101 clinical data until the online abstract release on November 11, 2021.

Details of the abstract presentations are as follows:

**Abstract #:** CTIM-29

**Abstract Title:**

Clinical evaluation of chlorotoxin-directed CAR T cells for patients with recurrent glioblastoma

**Presentation Date:** Friday November 19, 2021



**Abstract #:** EXTH-10

**Abstract Title:**

Exploration of a novel toxin-incorporating CAR T cell: how does chlorotoxin recognize glioblastoma cells?

**Presentation Date:** Friday November 19, 2021

**Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.**

**ABOUT CHIMERIC THERAPEUTICS**

Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy for the treatment of patients with Glioblastoma (GBM). CHM 1101 was developed by scientists at the City of Hope Medical Centre in California where it is currently being studied in a phase 1 clinical trial.

Chimeric also recently announced the expansion of their pipeline with the exclusive licensing of CHM 2101, a novel, 3rd generation CDH17 CAR T invented at the University of Pennsylvania. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in 2022 in Neuroendocrine Tumours, Colorectal, Pancreatic and Gastric Cancer.

Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

**CONTACT**

Investors

Jennifer Chow  
Chief Executive Officer and Managing Director  
Chimeric Therapeutics  
P: +9087238387  
E: [jchow@chimerictherapeutics.com](mailto:jchow@chimerictherapeutics.com)  
W: [www.chimerictherapeutics.com](http://www.chimerictherapeutics.com)

Media

Matthew Wright  
NWR Communications  
P: +61 451 896 420  
E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)